Floatz Rating
D30/100
Confidence
Indicative
Sponsor
General Hospital of Shenyang Military Region
Modality
Small molecule
Development Phase
N/A
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
15Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06483737CT.gov Human Albumin Infusion in Liver Cirrhosis and Overt Hepatic Encephalopathy (HACHE) | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hepatic Encephalopathy
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| ARG (this asset) | General Hospital of Shenyang Military Region | N/A | D · 30 |
| L-Ornithine L-Aspartate | Jinnah Postgraduate Medical Centre | P4 | BBB |
| Rifaximin | General Hospital of Shenyang Military Region | P4 | BBB |
| Lactulose | General Hospital of Shenyang Military Region | P4 | BBB |
| Normal Human Serum Albumin | General Hospital of Shenyang Military Region | P4 | BB |
| L-Ornithine-L-Aspartate | Qurratul Ain Jamil | P4 | BB |
| Lactose | Centro Regional para el Estudio de las Enfermedades Digestivas | P4 | BB |
| Ornithine | Imperial College London | P4 | BB |
| Blood, Whole | Imperial College London | P4 | BB |
+38 more in the Hepatic Encephalopathy cohort
Other indications for ARG
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Limb Ischemia | — | P4 | BB · 69 |
| Sickle Cell Disease | — | P3 | BB · 69 |
| Mitochondrial Disease | — | P4 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. ARG in Hepatic Encephalopathy. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/arg-hepatic-encephalopathy
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →